These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 31609782)

  • 1. Morphologic Patterns and the Correlation With MYD88 L265P, CD79B Mutations in Primary Adrenal Diffuse Large B-Cell Lymphoma.
    Chen Z; Zou Y; Liu W; Guan P; Tao Q; Xiang C; Zhang W; Ye Y; Yan J; Zhao S
    Am J Surg Pathol; 2020 Apr; 44(4):444-455. PubMed ID: 31609782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MYD88, CD79B, and CARD11 gene mutations in CD5-positive diffuse large B-cell lymphoma.
    Takeuchi T; Yamaguchi M; Kobayashi K; Miyazaki K; Tawara I; Imai H; Ono R; Nosaka T; Tanaka K; Katayama N
    Cancer; 2017 Apr; 123(7):1166-1173. PubMed ID: 27915469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frequent MYD88 L265P and CD79B Mutations in Primary Breast Diffuse Large B-Cell Lymphoma.
    Taniguchi K; Takata K; Chuang SS; Miyata-Takata T; Sato Y; Satou A; Hashimoto Y; Tamura M; Nagakita K; Ohnishi N; Noujima-Harada M; Tabata T; Kikuti YY; Maeda Y; Nakamura N; Tanimoto M; Yoshino T
    Am J Surg Pathol; 2016 Mar; 40(3):324-34. PubMed ID: 26752547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Frequency of MYD88 and CD79B mutations, and MGMT methylation in primary central nervous system diffuse large B-cell lymphoma.
    Zheng M; Perry AM; Bierman P; Loberiza F; Nasr MR; Szwajcer D; Del Bigio MR; Smith LM; Zhang W; Greiner TC
    Neuropathology; 2017 Dec; 37(6):509-516. PubMed ID: 28856744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MYD88, CARD11, and CD79B Oncogenic Mutations are Rare Events in the Indian Cohort of De Novo Nodal Diffuse Large B-Cell Lymphoma.
    Aggarwal V; Das A; Bal A; Srinivasan R; Das R; Prakash G; Malhotra P; Varma S
    Appl Immunohistochem Mol Morphol; 2019 Apr; 27(4):311-318. PubMed ID: 29734251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD79B and MYD88 mutations in diffuse large B-cell lymphoma.
    Kim Y; Ju H; Kim DH; Yoo HY; Kim SJ; Kim WS; Ko YH
    Hum Pathol; 2014 Mar; 45(3):556-64. PubMed ID: 24444466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A single-centre, real-world study of BTK inhibitors for the initial treatment of MYD88
    Deng T; Zhang S; Xiao M; Gu J; Huang L; Zhou X
    Cancer Med; 2024 Feb; 13(4):e7005. PubMed ID: 38457222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary diffuse large B-cell lymphomas of central nervous system exhibit remarkably high prevalence of oncogenic MYD88 and CD79B mutations.
    Yamada S; Ishida Y; Matsuno A; Yamazaki K
    Leuk Lymphoma; 2015 Jul; 56(7):2141-5. PubMed ID: 25347427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patients with primary breast and primary female genital tract diffuse large B cell lymphoma have a high frequency of MYD88 and CD79B mutations.
    Cao XX; Li J; Cai H; Zhang W; Duan MH; Zhou DB
    Ann Hematol; 2017 Nov; 96(11):1867-1871. PubMed ID: 28803429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nomogram for predicting survival of patients with diffuse large B-cell lymphoma.
    Fujii K; Inagaki A; Masaki A; Sugiura M; Suzuki T; Ishida T; Kusumoto S; Iida S; Inagaki H
    Ann Hematol; 2024 Jun; 103(6):2041-2050. PubMed ID: 38411628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biological and Clinical Relevance of Associated Genomic Alterations in MYD88 L265P and non-L265P-Mutated Diffuse Large B-Cell Lymphoma: Analysis of 361 Cases.
    Dubois S; Viailly PJ; Bohers E; Bertrand P; Ruminy P; Marchand V; Maingonnat C; Mareschal S; Picquenot JM; Penther D; Jais JP; Tesson B; Peyrouze P; Figeac M; Desmots F; Fest T; Haioun C; Lamy T; Copie-Bergman C; Fabiani B; Delarue R; Peyrade F; André M; Ketterer N; Leroy K; Salles G; Molina TJ; Tilly H; Jardin F
    Clin Cancer Res; 2017 May; 23(9):2232-2244. PubMed ID: 27923841
    [No Abstract]   [Full Text] [Related]  

  • 12. Deciphering the Prognostic Significance of MYD88 and CD79B Mutations in Diffuse Large B-Cell Lymphoma: Insights into Treatment Outcomes.
    Xie Z; Qin Y; Chen X; Yang S; Yang J; Gui L; Liu P; He X; Zhou S; Zhang C; Tang L; Shi Y
    Target Oncol; 2024 May; 19(3):383-400. PubMed ID: 38643457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MYD88 expression and L265P mutation in diffuse large B-cell lymphoma.
    Choi JW; Kim Y; Lee JH; Kim YS
    Hum Pathol; 2013 Jul; 44(7):1375-81. PubMed ID: 23380077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MYD88 L265P Mutations, But No Other Variants, Identify a Subpopulation of DLBCL Patients of Activated B-cell Origin, Extranodal Involvement, and Poor Outcome.
    Rovira J; Karube K; Valera A; Colomer D; Enjuanes A; Colomo L; Martínez-Trillos A; Giné E; Dlouhy I; Magnano L; Delgado J; Martínez A; Villamor N; Campo E; López-Guillermo A
    Clin Cancer Res; 2016 Jun; 22(11):2755-64. PubMed ID: 26792260
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutational frequencies of CD79B and MYD88 vary greatly between primary testicular DLBCL and gastrointestinal DLBCL.
    Frick M; Bettstetter M; Bertz S; Schwarz-Furlan S; Hartmann A; Richter T; Lenze D; Hummel M; Dreyling M; Lenz G; Gaumann A
    Leuk Lymphoma; 2018 May; 59(5):1260-1263. PubMed ID: 28868954
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinicopathological features of 49 primary gastrointestinal diffuse large B-cell lymphoma cases; comparison with location, cell-of-origin, and frequency of MYD88 L265P.
    Nagakita K; Takata K; Taniguchi K; Miyata-Takata T; Sato Y; Tari A; Ohnishi N; Noujima-Harada M; Omote S; Nakamura N; Iwamuro M; Maeda Y; Okada H; Tanimoto M; Yoshino T
    Pathol Int; 2016 Aug; 66(8):444-52. PubMed ID: 27439595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathologic significance of MYD88 L265P mutation in diffuse large B-cell lymphoma: a meta-analysis.
    Lee JH; Jeong H; Choi JW; Oh H; Kim YS
    Sci Rep; 2017 May; 7(1):1785. PubMed ID: 28496180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Prognostic Significance of CD79B Mutation in Diffuse Large B-Cell Lymphoma: A Meta-analysis and Systematic Literature Review.
    Xu PP; Shen R; Shi ZY; Cheng S; Wang L; Liu Y; Zhang L; Huang R; Ma X; Wu X; Yao H; Yu Y; Zhao WL
    Clin Lymphoma Myeloma Leuk; 2022 Dec; 22(12):e1051-e1058.e1. PubMed ID: 36182550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD79B Y196 mutation is a potent predictive marker for favorable response to R-MPV in primary central nervous system lymphoma.
    Yamaguchi J; Ohka F; Lushun C; Motomura K; Aoki K; Takeuchi K; Nagata Y; Ito S; Mizutani N; Ohno M; Suzaki N; Takasu S; Seki Y; Kano T; Wakabayashi K; Oyama H; Kurahashi S; Tanahashi K; Hirano M; Shimizu H; Kitano Y; Maeda S; Yamazaki S; Wakabayashi T; Kondo Y; Natsume A; Saito R
    Cancer Med; 2023 Mar; 12(6):7116-7126. PubMed ID: 36478416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clonal Evolution in Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System.
    Garcia-Reyero J; Martinez Magunacelaya N; Gonzalez Pereña A; Marcos Gonzalez S; Teran-Villagra N; Azueta A; Batlle A; Gonzalez de Villambrosia S; Revert Arce J; Montes-Moreno S
    Appl Immunohistochem Mol Morphol; 2020 Sep; 28(8):e68-e71. PubMed ID: 29629945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.